Literature DB >> 7046776

Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure.

A B Atkinson, A M Cumming, J J Brown, R Fraser, B Leckie, A F Lever, J J Morton, J I Robertson.   

Abstract

1 The ability of captopril, 150 mg three times daily by mouth, to effect sustained reduction in plasma angiotensin II, with converse increases in circulating angiotensin I, and in active, inactive and total renin concentrations, has been assessed. 2 During prolonged treatment with captopril alone, and 12 h after the last dose of the drug, plasma angiotensin II remained approximately one-sixth of basal concentrations, while angiotensin I and renin concentrations were proportionately increased. However, further increases in angiotensin I, and in active, inactive and total renin concentrations, were seen 2 and 6 h after the morning dose of 150 mg captopril. 3 Inter-dose variations in plasma aldosterone and blood pressure were not closely related to concurrent variations in the renin-angiotensin system. 4 Arguments are presented for relying on measurements of plasma renin and angiotensin concentrations rather than of renin activity or aldosterone in assessing the effectiveness of converting enzyme inhibition.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7046776      PMCID: PMC1402024          DOI: 10.1111/j.1365-2125.1982.tb01878.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

Review 1.  Control of aldosterone secretion.

Authors:  R Fraser; J J Brown; A F Lever; P A Mason; J I Robertson
Journal:  Clin Sci (Lond)       Date:  1979-05       Impact factor: 6.124

2.  The measurement of angiotensin-converting enzyme in subjects receiving captopril.

Authors:  J E Roulston; G A MacGregor
Journal:  N Engl J Med       Date:  1980-08-14       Impact factor: 91.245

Review 3.  Captopril in the treatment of clinical hypertension and cardiac failure.

Authors:  A B Atkinson; J I Robertson
Journal:  Lancet       Date:  1979-10-20       Impact factor: 79.321

4.  Increase of plasma renin-substrate concentration after infusion of angiotensin in the rat.

Authors:  M Khayyall; J MacGregor; J J Brown; A F Lever; J I Robertson
Journal:  Clin Sci       Date:  1973-01       Impact factor: 6.124

5.  Estimation of angiotensin II concentration in human plasma by radioimmunoassay. Some applications to physiological and clinical states.

Authors:  G Düsterdieck; G McElwee
Journal:  Eur J Clin Invest       Date:  1971-11       Impact factor: 4.686

6.  Measurement of concentrations of angiotensin I in human blood by radioimmunoassay.

Authors:  M A Waite
Journal:  Clin Sci       Date:  1973-07       Impact factor: 6.124

7.  A comparison of double-isotope derivative and radioimmunological estimation of plasma aldosterone concentration in man.

Authors:  R Fraser; S Guest; J Young
Journal:  Clin Sci Mol Med       Date:  1973-09

8.  The relation of arterial pressure and plasma angiotensin II concentration. A change produced by prolonged infusion of angiotensin II in the conscious dog.

Authors:  B L Bean; J J Brown; J Casals-Stenzel; R Fraser; A F Lever; J A Millar; J J Morton; B Petch; A J Riegger; J I Robertson; M Tree
Journal:  Circ Res       Date:  1979-04       Impact factor: 17.367

9.  A microassay for active and total renin concentration in human plasma based on antibody trapping.

Authors:  J A Millar; B J Leckie; J J Morton; J Jordan; M Tree
Journal:  Clin Chim Acta       Date:  1980-02-14       Impact factor: 3.786

10.  Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril.

Authors:  B Waeber; H R Brunner; D B Brunner; A L Curtet; G A Turini; H Gavras
Journal:  Hypertension       Date:  1980 Mar-Apr       Impact factor: 10.190

View more
  8 in total

Review 1.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 2.  ACE inhibitors for heart failure: a question of dose.

Authors:  J G Cleland; P A Poole-Wilson
Journal:  Br Heart J       Date:  1994-09

3.  Converting enzyme inhibitors in hypertension and heart failure.

Authors:  H J Dargie; S G Ball; A B Atkinson; J I Robertson
Journal:  Br Heart J       Date:  1983-04

4.  Captopril: five years on.

Authors:  G P Hodsman; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-24

5.  Concentration effect modelling with converting enzyme inhibitors in man.

Authors:  A W Kelman; J L Reid; J A Millar
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

6.  Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

Authors:  G P Hodsman; J R Zabludowski; C Zoccali; R Fraser; J J Morton; G D Murray; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

7.  Converting-enzyme inhibitor enalapril (MK421) in treatment of hypertension with renal artery stenosis.

Authors:  G P Hodsman; J J Brown; D L Davies; R Fraser; A F Lever; J J Morton; G D Murray; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1982-12-11

8.  Enalapril in the treatment of hypertension with renal artery stenosis.

Authors:  G P Hodsman; J J Brown; A M Cumming; D L Davies; B W East; A F Lever; J J Morton; G D Murray; I Robertson; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.